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Sequence-based design of a peptide probe for the APC tumor
suppressor protein
Victoria Allen Sharma*, Jennifer Logan†, David S. King‡, Ray White†
and Tom Alber*
Background: Proteins form specific associations, but predictive rules for
protein pairing are generally unknown. Here, we describe amino-acid sequence
patterns capable of mediating specific pairing of a widespread protein motif:
the parallel, dimeric, α-helical coiled coil. The pairing rules were tested by
designing a 54-residue peptide (anti-APCp1) that is predicted to dimerize
preferentially with a coiled-coil sequence from the adenomatous polyposis coli
(APC) tumor suppressor protein.
Results: As judged by circular dichroism, ultracentrifugation and native gel
electrophoresis, anti-APCp1 formed a specific, helical, dimeric complex with the
target APC coiled coil. On western blots of APC fragments expressed in
Escherichia coli, the designed peptide detected a pattern of bands identical to
the pattern detected by an antibody directed against the APC coiled coil.
Peptide-mediated precipitation experiments showed that anti-APCp1 bound
and sequestered wild-type and mutant APC proteins in extracts of human colon
cancer cell lines. In addition, binding of the designed peptide preserved native
APC–β-catenin complexes. 
Conclusions: These biochemical experiments demonstrate that the anti-APC
peptide preferentially forms a heterodimeric coiled coil with mutant and full-
length APC proteins. The specificity of the designed peptide is sufficient to
support several applications that commonly use antibodies. The observed
specificity of anti-APCp1 validates the pairing rules used as the basis for the
probe design, and it suggests that residues in the core positions of coiled coils
help impart pairing selectivity. 
Background
Specific molecular probes, such as antibodies and oligonu-
cleotides, have broad applications in molecular biology
and medicine. The advent of new probes targeted for pro-
teins, however, is limited by the absence of generalizable
recognition rules. Oligomerization specificity has been
especially well studied for the coiled coil, a simple struc-
tural motif in which α-helices wrap around each other in a
left-handed supercoil [1–4]. Approximately 1–2% of the
amino acids in proteins occur in coiled coils [1,3], which
are found in diverse functional contexts including tran-
scription factors, enzymes, motors, muscle proteins, inter-
mediate filaments, cellular and viral surface proteins and
tumor suppressors [1–3]. Coiled-coil sequences are charac-
terized by a seven-residue repeat, (a b c d e f g)n, in which
the first (a) and fourth (d) positions comprise the
hydrophobic core of the interhelical interface and, gener-
ally, polar residues at e and g flank the core. Although
they share a common structure, dimeric coiled coils pair
specifically [5]. This specificity has been demonstrated in
wild-type protein sequences [6–8] and synthetic model
systems [9–11].
To develop pairing rules that could guide the design of
complementary coiled-coil peptides, we relied on thermo-
dynamic measurements of specificity [5,12–14] and covari-
ation patterns in coiled-coil sequences (Figure 1). In both
natural and model coiled coils, specific associations have
been attributed to destabilizing ionic interactions in the
homodimers that are replaced with more favorable con-
tacts in the heterodimer [5,12–18]. Consequently, our
peptide design included charged amino acids at g and suc-
ceeding e¢ positions that could form ion pairs in the het-
erodimer and repulsive ionic interactions in the designed
peptide homodimer [12]. 
In contrast to the g and e positions, little specificity has
been ascribed to core residue contacts [5,7,19,20]. In the
heterodimer formed by the Fos and Jun leucine zippers,
for example, three heterotypic pairs of core residues
appear to impart none of the observed preference of the
chains for each other [5]. This is surprising considering
that the core residues form the majority of interhelical
contacts [4] and that mutations of core residues have dra-
matic effects on stability and oligomerization [21–26]. To
Addresses: *Department of Molecular and Cell
Biology, 229 Stanley Hall #3206, University of
California, Berkeley, California 94720-3206, USA.
†Department of Oncological Sciences, Huntsman
Cancer Institute, University of Utah School of
Medicine, Salt Lake City, Utah 84112-5330, USA.
‡Howard Hughes Medical Institute, Department of
Molecular and Cell Biology, University of California,
Berkeley, California 94720-3202, USA.
Correspondence: Tom Alber
E-mail: tom@ucxray6.berkeley.edu 
Received: 13 March 1998
Revised: 18 May 1998
Accepted: 18 May 1998
Published: 18 June 1998
Current Biology 1998, 8:823–830
http://biomednet.com/elecref/0960982200800823
© Current Biology Ltd ISSN 0960-9822
Research Paper 823
obtain principles for core complementation, we analyzed
the sequences of the coiled-coil domains in cytokeratins
that form obligate heterodimers [27,28]. Uneven occur-
rences of heterotypic and homotypic pairing provided evi-
dence for core-mediated specificity and revealed the
identities of preferred interhelical neighbors (Figure 1). 
The ability of these two simple patterns — complemen-
tary (and repulsive) charges and heterotypic core con-
tacts — to direct heterotypic pairing was investigated by
designing a peptide complementary to the coiled-coil
domain of the adenomatous polyposis coli (APC) tumor
suppressor protein. Mutations in the APC gene are associ-
ated with 75% of sporadic colon tumors [29] and with a
familial predisposition to colon cancer [30]. Alternative
mRNA splicing predicts a family of large APC proteins
(~2800 amino acids) that are thought to regulate cell
adhesion and transcription in part by binding and down-
regulating β-catenin [31–35]. The amino-terminal 55
amino acids of the APC protein form a coiled coil that
mediates homodimerization [36,37]. The majority of
disease-associated mutations predict truncated proteins
[29,30,38]; therefore, tumorigenic as well as wild-type
APC proteins contain the coiled-coil domain targeted by
our anti-APC peptide.
Results and discussion
To design the anti-APC peptide (anti-APCp1), we made
20 mutations in the sequence of the first 55 amino acids of
APC (Figure 2). Five changes were made in the a and d
positions — Ala2Met, Tyr6Gly, Asn30His, Ala41Ile and
Met44Ala (Figure 2b) — based on covariation patterns at a
and d positions of keratin type I and type II heterodimers
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Figure 1
Covariation in the core residues of coiled coils in the heterodimeric
cytokeratins. Core amino acids are listed in the single-letter code, and
the number of occurrences of each interhelical a–a¢ (top) and d–d¢
(bottom) residue pair in the heterodimers is tabulated. Numbers on the
diagonals denote homotypic amino-acid pairs in the heterodimer
sequences. Amino acids with a high relative frequency of heterotypic
pairing and a low relative frequency of homotypic pairing — such as Ala,
Ile, Met and Ser at the a position and Ala, Phe, His, Ile, Met, Asn and
Val at the d position — provide evidence that core residues can confer
specificity to coiled-coil dimerization. Off-diagonal combinations
expected to favor the heterodimer and homotypic pairs expected to
disfavor the designed homodimer are underlined.
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Figure 2
Contacts that form the basis for the anti-APCp1 design. (a) Schematic
diagram of a coiled coil showing alternating a–a¢ and d–d¢ layers
(gray) in the core and surrounding g and succeeding e¢ residues (blue)
that can form interhelical electrostatic interactions (black bars). White
balls correspond to surface b, c and f positions that do not make
substantial interhelical contacts. Supercoiling of the two helices is
omitted for simplicity. (b) Helical wheel diagram showing the
sequences of the target APC-55 peptide (left) and the designed anti-
APCp1 probe (right). The residues in the wild-type APC-55 peptide
are shown in outlined letters, and the sequence changes in anti-
APCp1 are shown in bold. The sequences begin with Ala2 (APC-55)
and Met2 (anti-APCp1) at position d. The view is from the amino
terminus along the superhelical axis. The a–a¢ and d–d¢ pairs form
alternating layers, and potential interhelical ion pairs between g and
succeeding e¢ residues are marked with arrows. 
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(Figure 1). Eight changes at g and e positions — Ser5Lys,
Leu10Lys, Gln12Glu, Lys17Glu, Glu26Lys, Ser31Lys,
His33Lys, and Glu38Lys (Figure 2b) — were made to
destabilize anti-APCp1 homodimers and form ion pairs
upon heterodimerization with APC. Two additional
changes at the e and g positions — Val47Met and
Gln52Tyr — were made to increase stability [39] and
introduce a chromophore. 
Because they make no interhelical contacts, changes at the f
positions have little effect on pairing specificity [4]. Gln25,
Asn32, and Glu46 at f positions were changed to Lys to
increase net charge to aid in separation of the heterodimer.
These mutations also increased the helical propensity of
the complementary sequence [39]. The f position changes
Gly53Ala and Met18Tyr were made to reduce terminal
fraying [40] and add a chromophore, respectively. 
The preferential interaction of anti-APCp1 with the APC
amino terminus was demonstrated in vitro by thermal
denaturation, sedimentation equilibrium and native gel
electrophoresis. Circular dichroism (CD) spectra indicated
that the wild-type APC amino terminus (APC-55), the
designed peptide probe and an equimolar mixture of the
two peptides were at least 95% helical (Figure 3a). The
apparent melting temperature (Tm) of the heterodimer
was more than 10°C higher than the average of the two
homotypic species at half the concentration, suggesting
that the anti-APCp1 peptide preferentially formed het-
erodimers with the wild-type APC-55 (Table 1). The
increased thermal stability of the heteromeric mixture was
observed at different peptide concentrations (Table 1),
consistent with formation of hetero-oligomers. 
Equilibrium sedimentation studies confirmed the het-
eromeric mixture to be a dimer, as expected from our
dimeric coiled-coil design (Table 1). Anti-APCp1 by itself,
however, formed a mixture of oligomers in solution, as
indicated by an average molecular weight larger than
expected for a dimer (Table 1) and systematic residuals
from a dimer fit (data not shown). Consequently, the
dimeric nature of the 1:1 mixture of APC-55 and anti-
APCp1 suggested that binding to the wild-type target
peptide reduced the concentration of higher order
oligomers of the probe. 
The most direct measure of heterodimer specificity was
provided by native acrylamide gel electrophoresis. Com-
pared with the APC-55 and anti-APCp1 peptides alone, an
equimolar mixture of the two peptides yielded a distinct
species with intermediate mobility (Figure 3c). The
appearance of the heterodimer band with concomitant loss
of both homomeric species demonstrates the high speci-
ficity of the designed peptide. Urea denaturation at 20°C
and pH 7.0, monitored by CD, suggested upper limits for
the dissociation constants (Kds) of APC-55, anti-APCp1
and the APC-55–anti-APCp1 heterodimer of 6 nM,
0.4 nM and 0.3 nM, respectively (data not shown). Thus,
the affinity of anti-APCp1 for APC-55 is 20-fold greater
than the wild-type affinity.
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The APC-55–anti-APCp1 complex is helical, thermally stable and
specific. (a) CD spectra at 75 µM total peptide concentration of
APC-55, anti-APCp1 or an equimolar mixture of APC-55 and anti-
APCp1. All three species are greater than 95% helical, consistent with
the coiled-coil design. (b) Thermal denaturation monitored by CD at
222 nm of APC-55 and anti-APCp1 peptides and an equimolar mixture
of the peptides. The mixture of the two peptides shows an increase in
Tm of 8°C over the wild-type homodimer. (c) Native gel
electrophoresis: lane 1, APC-55; lane 2, anti-APCp1; lane 3, an
equimolar mixture of APC-55 and anti-APCp1. The mixture of the two
peptides yields a new species with intermediate mobility, and neither of
the two homomeric species is detected. The mobilities of the individual
peptides and the equimolar mixture are consistent with calculated
isoelectric points of 10.8 (anti-APCp1), 10.0 (heterodimer) and 4.8
(APC-55). The single band for the anti-APCp1 peptide may reflect a
common electrophoretic mobility for dimer and trimer species or a shift
in oligomerization equilibrium at the pH (4.0) of the gel. The detection
limit of the Coomassie stain gives a lower limit of ~100:1 for the
specificity of anti-APCp1 for APC-55.
The ability of anti-APCp1 to distinguish APC from other
cellular proteins and compete effectively with homotypic
pairs of full-length APC subunits was investigated by
western blotting and affinity purification. Anti-APCp1 and
antibodies against the amino terminus of APC detected
similar patterns of glutathione-S-transferase (GST)–APC
fusion proteins expressed in Escherichia coli (Figure 4).
Western blots developed with either the designed peptide
or the antibody revealed common regions of proteolytic sus-
ceptibility within the first 373 amino acids of APC (Figure 4,
lane 3). In contrast to the antibody, the anti-APCp1 peptide
also bound to a GST fusion protein containing the designed
probe sequence itself (Figure 4, lane 4). Thus, the 20
sequence changes in anti-APCp1 apparently abolished the
antibody epitope but preserved the capacity for homo-
oligomerization. These results suggest not only that the
designed peptide forms a coiled-coil interaction with the
APC amino terminus, but also that this coiled coil forms in
preference to interactions with E. coli proteins.
Because of its large size (approximately 312 kDa) and low
abundance [41], detection of APC protein in human cells
presents special challenges. No APC species were
detected when peptide-mediated or antibody-mediated
precipitates of human tumor cell lines were separated by
gel electrophoresis and silver-stained or blotted and
stained with Ponceau S (data not shown). Moreover,
autoradiographs of precipitations from [35S]methionine-
labeled lysates revealed a similar pattern of bands when
either biotinylated anti-APCp1 or biotin alone were used
for precipitation (data not shown).
Low endogenous amounts of full-length and mutant APC
polypeptides were detected, however, by western blotting
peptide-mediated precipitations from colon cancer cell
lines (Figure 5). Similar patterns and yields of APC
polypeptides were captured with biotinylated anti-APCp1
or a biotinylated monoclonal antibody specific for the APC
amino terminus (Figure 5a). No APC was detected when
affinity precipitations were carried out with the peptide
alone (Figure 5, lane 3) or biotin alone (Figure 5, lane 4).
Thus, the affinity precipitation of APC was specific to the
biotin–anti-APCp1 conjugate. Because the amino-termi-
nal, coiled-coil sequence targeted by anti-APCp1 is
present in tumor-associated truncation mutants, the dis-
tinct electrophoretic mobilities of the species detected by
the designed peptide distinguish wild-type from tumori-
genic APC variants (Figure 5).
These results indicate that the biotinylated anti-APCp1
peptide pairs effectively with full-length APC polypep-
tide chains. As previously reported for APC-specific 
antibodies [31,33], the anti-APCp1 peptide coprecipitated
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Figure 4
Western blots of APC fusion proteins
expressed in E. coli. Blots were probed using
either (a) biotinylated anti-APCp1, or (b) a
monoclonal antibody, AB-1, that recognizes
amino acids 1–29 of the APC protein. (c) The
Coomassie-stained gel used to generate the
blots. The molecular weights of protein
standards are indicated in kDa. (a–c) Lane 1,
GST only; lane 2, GST–APC-55; lane 3,
GST–APC-373 (GST fusion with the first 373
amino acids of APC); lane 4, GST–anti-
APCp1. The biotinylated anti-APCp1 detects
the same APC fragments as the antibody –
lanes 2 and 3 in (a,b) — and also binds
GST–anti-APCp1 — lane 4 in (a). The designed
peptide distinguishes APC sequences from all
other E. coli proteins on the blot.
(a) (b) (c) kDa1 2 3 4 1 2 3 4 1 2 3 4
- 97
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- 30
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Table 1
Peptide oligomerization and stability.
Peptide Apparent Mr (Da)* Apparent Tm (± 1°C)
8.0 µM 20.0 µM 75.0 µM
APC-55 12,400 36.3 40.0 46.5
Anti-APCp1 14,000 51.5 58.6 66.4
APC-55–anti-APCp1 13,300 52.9 57.5 63.6
*Molecular weights were analyzed by equilibrium centrifugation. The
expected molecular weights of the APC-55 homodimer, anti-APCp1
homodimer, and the APC-55—anti-APCp1 heterodimer were 12,000,
12,500 and 12,300 Da, respectively. Apparent molecular weights (Mr)
for three different concentrations of each species were calculated and
averaged. The lack of systematic residuals to a dimer fit (data not
shown) indicates that both the wild-type peptide and the APC-55–anti-
APCp1 mixture form dimers. In contrast, the anti-APCp1 peptide alone
forms a mixture of oligomers. Apparent melting temperature (Tm) was
determined by CD at 222 nm. The observed increase in apparent Tm
for all species with increased concentration is consistent with the
formation of oligomers. 
β-catenin (Figure 5), a protein that recognizes motifs in
the central third of the APC sequence [31,33]. Although
binding of anti-APCp1 to endogenous APC protein dis-
rupts the homodimeric, amino-terminal APC coiled coil
(Figure 3), APC–β-catenin complexes survived this dis-
ruption (Figure 5). Moreover, only a subset of β-catenin
species coprecipitated from tumor cell lines (Figure 5),
suggesting that anti-APCp1 does not bind directly to
every protein in the extracts. Consistent with this conclu-
sion, antibodies specific for E-cadherin or the 20S protea-
some p32 subunit failed to stain proteins precipitated by
anti-APCp1 (data not shown). 
Conclusions
The specificity and stability of the anti-APCp1 heterodimer
validate the two key design principles of optimized electro-
static interactions and complementary core packing. The
interpretation of core contact patterns (Figure 1) is ham-
pered by the modest number of heptad pairs, the homolo-
gies among the underlying keratin sequences and the
assumption that the sequence context exerts a limited
influence on the pair preference. Moreover, although the
covariation analysis reflects only a–a¢ and d–d¢ pairs, some
core sidechains (for example, charged residues) are accom-
modated in coiled coils by interactions with residues in
other heptad positions [7,42]. Coiled-coil stability and
oligomerization state are sensitive to core mutations
[5,23,43]. In this context, the stability of the APC-55–anti-
APCp1 heterodimer supports the efficacy of our design
method. Greater understanding of the basis for pairing
specificity will undoubtedly lead to better design rules.
In contrast to anti-APCp1, other protein-targeted ligands
require experimental selections. Iterative, system-specific
binding assays are necessary to obtain protein ligands from
phage display or chemical libraries, and antibodies
undergo selection in vivo [44,45]. Unlike antibodies, com-
plementary coiled-coil peptides are small, relatively inex-
pensive, and stable without disulfide bonds. The
designed coiled coils also necessarily disrupt the target
structure [46–50]. Heterotypic coiled-coil peptides
combine the utility of a sequence-based design and the
simplicity of chemical synthesis. These properties may
facilitate diverse applications in vitro and in vivo. Coiled-
coil sequences are readily identified by computer methods
[1–3], making this large family of proteins amenable to
complementary peptide design. 
Materials and methods
Sequence covariation analysis and complementary peptide
design
Heptad repeats in the sequences of obligate heterodimers of type I and
type II keratins [27,28] were assigned by the program PAIRCOIL [3]
and 312 heptads were aligned by homology. Four pairs (comprising
four known interacting heterodimers) of human keratin sequences were
used in the analysis: K8–K18, K4–K13, K5–K14 and K1–K10.
Sequences are available in the Swissprot database with the following
accession numbers: K8 (P05787), K18 (P05783), K4 (P19013), K13
(P13646), K5 (P13647), K14 (P02533), K1 (P04264), and K10
(P13645). Of the twenty changes in anti-APCp1, five were made to the
a and d positions based on covariation sequence analysis and eight
changes at the e and g positions were made to introduce repulsive
ionic interactions in the anti-APC homodimer that are relieved in the
parallel heterodimer. Two additional changes at the e and g positions
and five changes at the non-interacting f position were made to add
chromophores or to increase the helical propensity or the net charge of
the designed peptide.
Peptide expression, synthesis and purification
APC-55, a peptide corresponding to amino acids 2–55 of human APC,
was produced by expression in E. coli [36]. Cell pellets resuspended in
80 mM Tris HCl pH 8.0, 0.2 mM EDTA, 20 mM KCl were lysed by 
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Anti-β-cateninAnti-APC Anti-β-cateninAnti-APC Anti-β-catenin
Western blots of precipitations of APC from human colon cancer cell
lines. APC was precipitated from three different cell lines: (a) 293,
which expresses full-length APC, (b) DLD-1, which contains a stop at
codon 1417 and expresses a truncated APC molecule of 190 kDa,
and (c) HT-29, which expresses two truncated APC molecules of
approximately 100 and 200 kDa [53]. Blots were probed with an APC
antibody or a β-catenin antibody as shown. The total lysate is shown in
lane 1. Precipitations were performed using: lane 2, biotinylated anti-
APCp1; lane 3, anti-APCp1 without biotin; lane 4, biotin alone; lane 5,
the anti-APC antibody Ab-1; and lane 6, a non-specific mouse
immunoglobulin G. The molecular weights of protein standards are
indicated in kDa. The biotinylated anti-APCp1 peptide precipitated
truncation mutants and full-length APC at endogenous cell
concentrations, demonstrating the affinity and specificity of the
designed probe. The biotinylated peptide also coprecipitated two 
β-catenin species (right panels) previously demonstrated to associate
with APC [31–35].
sonication in a dry ice/ethanol bath. The pH was lowered to 2 by drop-
wise addition of concentrated HCl, and the acidified lysate was cleared
by centrifugation. The supernatant was neutralized, diluted twofold and
loaded onto DEAE cellulose. The column was developed with
10–1000 mM KCl. The peak fractions of peptide were concentrated
and purified by reversed-phase high performance liquid chromatogra-
phy (HPLC) [36]. Purity and amino-acid composition of the peptide
were confirmed by electrospray mass spectrometry. 
Complementary peptides were synthesized with Fmoc chemistry using
an Applied Biosystems 431A peptide synthesizer. Met residues in anti-
APCp1 were replaced with isosteric norleucine (Nle) to prevent side-
chain oxidation. Anti-APCp1 conjugated to biotin contains Met instead
of Nle, an additional Leu8Val mutation and Glu–Asp–Glu (wild-type
APC sequence) at the peptide carboxyl terminus. This probe was indis-
tinguishable from anti-APCp1 in native gel experiments and CD experi-
ments (data not shown). The anti-APCp1 peptide was biotinylated on
the resin with succinimidyl-6-(biotinamido) hexanoate (Pierce) in
dimethylformamide. Peptides were purified by reversed-phase HPLC
using the same column and gradient as for the wild-type sequence. The
identity and purity of all peptides were assessed by electrospray mass
spectrometry; all masses measured were within 0.3 atomic mass units
of expected values.
Circular dichroism (CD) measurements
CD spectra were recorded in a 1 mm pathlength cuvette at 5°C using
an Aviv 62DS circular dichroism spectrophotometer. Peptide stocks
were diluted in 10 mM KPO4, 100 mM KF, pH 7.0. Thermal denatura-
tions were carried out in steps of 1–3°C with 2 min for equilibration
and 1 min for data averaging. Thermal transitions were > 90%
reversible. Apparent Tm was calculated as the maximum of the first
derivative of the CD signal at 222 nm with respect to T–1.
Equilibrium sedimentation
Ultracentrifugation experiments were carried out using a Beckman
X-LA ultracentrifuge. Absorbance was monitored at 215, 230 and
280 nm at peptide concentrations of 75, 150 and 250 µM in 10 mM
KPO4, 100 mM KF, pH 7.0. Apparent molecular weights were calcu-
lated using the program HID4000 [51] by simultaneously fitting the
three data sets recorded at different wavelengths. 
Native gel electrophoresis
Samples of the individual peptides and an equimolar mixture of the
peptides were prepared and diluted twofold in 0.2% (weight : volume)
methyl green, 20% glycerol, 750 mM β-alanine acetate pH 6.0. The
peptides (9.0 µg) were loaded at a total peptide concentration of
600 µM. Gels contained 7.5% acrylamide in 375 mM β-alanine
acetate, pH 4.0. Samples were run for 2 h at 100 volts, and the gels
were fixed with 2% glutaraldehyde and stained for at least 1 h in 0.2%
Coomassie brilliant blue in 50% methanol and 10% acetic acid
(volume : volume). Destaining was carried out overnight in the same
solvent lacking the dye.
Western blotting
Lysates of E. coli expressing GST alone or the GST–APC-55 polypep-
tide and pellets from lysates containing insoluble GST–APC-373 [36]
or GST–anti-APCp1 polypeptides were adjusted to 1 mg/ml and
diluted 10-fold in lysates from induced cells containing no APC
sequences. Each sample (5 µg) was electrophoresed on a 10%
Tricine–SDS polyacrylamide gel [52] and transferred to a 0.45 micron
nitrocellulose. Blots probed with anti-APCp1 were blocked for 1 h in
PNT buffer (10 mM phosphate, pH 8.0, 75 mM NaCl, 0.1% Tween-20)
containing 5% bovine serum albumin (BSA) and incubated for 1 h at
42°C with 5 nM biotinylated anti-APCp1 peptide in PNT buffer contain-
ing 1% BSA. After 30 min at room temperature in streptavidin-conju-
gated horseradish peroxidase (HRP) diluted 1:2000 in PNT, the blots
were washed three times for 15 min in PNT buffer and developed using
enhanced chemiluminescence (ECL) substrate (Amersham). Blots
probed with an anti-APC antibody were blocked for 1 h in TBST
(10 mM Tris pH 7.5, 137 mM NaCl, 0.1% Tween-20) containing 5%
BSA and incubated for 1 h at 42°C with anti-APC Ab-1 (1:2000;
Oncogene Science/Calbiochem) in TBST buffer containing 1% BSA.
After 30 min at room temperature in HRP-conjugated anti-mouse IgG
(1:30,000) in TBST, the blots were washed three times for 15 min in
TBST buffer and developed as above.
Peptide-mediated and antibody-mediated precipitation and co-
precipitation of endogenous APC and β-catenin
APC was precipitated from three different cell lines: 293, which
expresses full-length APC; DLD-1, which contains a mutation at codon
1417 and expresses a truncated APC molecule of approximately
190 kDa; and HT-29, which expresses two truncated APC molecules
of approximately 100 and 200 kDa [53]. Cells were harvested at
90–100% confluency, washed twice with ice-cold Dulbecco’s phos-
phate buffered saline (D-PBS, Gibco BRL) containing MgCl2 and
CaCl2, scraped into 15 ml ice cold D-PBS and pelleted in a Beckman
J-6 centrifuge for 5 min at 4°C. Cell pellets were resuspended in 1 ml
ice-cold phosphate buffer, pH 8, containing 0.1% NP-40, 40 µg/ml
Pefabloc SC (Boehringer Mannheim) and 10 µg/ml each of leupeptin,
pepstatin and aprotinin. The suspension was sonicated, then pelleted
for 15 min at 4°C in a microcentrifuge. 
For peptide-mediated precipitations, 2 nmol biotinylated anti-APCp1,
unbiotinylated anti-APCp1, or D-biotin were added on ice to aliquots of
cell lysate (aliquots typically contained 0.5–1 mg total protein by Bradford
assay). Streptavidin magnetic particles (1 mg; Boehringer Mannheim),
preblocked overnight in lysis buffer containing 5% BSA, were added to
each reaction and incubated, rocking, for 1 h at 4°C. Pellets were washed
five times in ice-cold lysis buffer and incubated for 10 min at 55°C in 10µl
PBS containing 0.1 mM D-biotin. SDS–PAGE sample buffer (10µl) was
added to each pellet and reactions were incubated for 5 min at 95°C. 
For antibody-mediated precipitations, 3 µg anti-APC Ab-1 or a non-spe-
cific mouse IgG1 antibody (Sigma) was added. After 30 min on ice,
protein-G–agarose (preblocked overnight with 5% BSA in lysis buffer)
was added to the lysates and allowed to incubate for 1 h, rocking, at 4°C.
Following five washes with ice-cold lysis buffer, protein-G–agarose pellets
were resuspended in 15 µl SDS–PAGE sample buffer and incubated for
5 min at 95°C. Precipitates were electrophoresed on a 6% Tris-glycine
polyacrylamide gel (Novex), electroblotted to nitrocellulose and probed.
Blots were blocked for 1 h in TBST containing 5% BSA and probed
with anti-APC antibody Ab-1, or a monoclonal anti-catenin antibody
(Transduction Laboratories). Anti-APC Ab-1 was diluted 1:150 in
TBST, 1% BSA and anti-catenin antibody was diluted 1:2000. Blots
were washed three times for 5 min each in TBST and incubated for 1 h
in HRP-conjugated rabbit anti-mouse IgG1 antibody (Pierce) diluted
1:30,000 in TBST and 1% BSA. After three 15 min washes in TBST,
blots were developed using ECL substrate (Amersham). 
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